{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T06:12:52Z","timestamp":1791526372931,"version":"4.3.4"},"reference-count":30,"publisher":"American Chemical Society (ACS)","issue":"7","license":[{"start":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T00:00:00Z","timestamp":1590105600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T00:00:00Z","timestamp":1590105600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T00:00:00Z","timestamp":1590105600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol. Pharmaceutics"],"published-print":{"date-parts":[[2020,7,6]]},"DOI":"10.1021\/acs.molpharmaceut.0c00093","type":"journal-article","created":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T22:04:31Z","timestamp":1590185071000},"page":"2345-2353","source":"Crossref","is-referenced-by-count":53,"title":["Characterization of Polysorbate Ester Fractions and Implications in Protein Drug Product Stability"],"prefix":"10.1021","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9443-7307","authenticated-orcid":true,"given":"Anthony","family":"Tomlinson","sequence":"first","affiliation":[{"name":"Pharmaceutical Development, Genentech, Inc., San Francisco, California 94080-4990, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isidro E.","family":"Zarraga","sequence":"additional","affiliation":[{"name":"Pharmaceutical Development, Genentech, Inc., San Francisco, California 94080-4990, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barth\u00e9lemy","family":"Demeule","sequence":"additional","affiliation":[{"name":"Pharmaceutical Development, Genentech, Inc., San Francisco, California 94080-4990, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2020,5,22]]},"reference":[{"key":"ref1\/cit1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2015.09.016"},{"key":"ref2\/cit2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1025771421906"},{"key":"ref3\/cit3","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-019-0312-3"},{"key":"ref4\/cit4","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-018-2430-5"},{"key":"ref5\/cit5","doi-asserted-by":"publisher","DOI":"10.1016\/j.chroma.2010.09.057"},{"key":"ref6\/cit6","doi-asserted-by":"publisher","DOI":"10.1021\/ac5009628"},{"key":"ref7\/cit7","unstructured":"Polysorbate 20.  United\nStates Pharmacopeia 2014, 1."},{"key":"ref8\/cit8","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.5b00311"},{"key":"ref9\/cit9","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.5b00310"},{"key":"ref10\/cit10","doi-asserted-by":"publisher","DOI":"10.1002\/jps.24144"},{"key":"ref11\/cit11","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600671211"},{"key":"ref12\/cit12","doi-asserted-by":"publisher","DOI":"10.1002\/jps.22290"},{"key":"ref13\/cit13","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-011-0385-x"},{"key":"ref14\/cit14","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1973.tb09135.x"},{"key":"ref15\/cit15","doi-asserted-by":"publisher","DOI":"10.1002\/jps.24054"},{"key":"ref16\/cit16","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-015-1670-x"},{"key":"ref17\/cit17","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2016.02.022"},{"key":"ref18\/cit18","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2016.02.029"},{"key":"ref19\/cit19","doi-asserted-by":"publisher","DOI":"10.5731\/pdajpst.2015.005942"},{"key":"ref20\/cit20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2016.09.033"},{"key":"ref21\/cit21","unstructured":"US\nFood and Drug Administration Novel Excipient Review Program Proposal; Request for Information\nand Comments.  Federal Register 2019, 84, 66669\u201366671."},{"key":"ref22\/cit22","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(86)90406-9"},{"key":"ref23\/cit23","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2019.12.016"},{"key":"ref24\/cit24","doi-asserted-by":"publisher","DOI":"10.1002\/jps.21190"},{"key":"ref25\/cit25","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpc.2016.03.003"},{"key":"ref26\/cit26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpc.2009.04.004"},{"key":"ref27\/cit27","doi-asserted-by":"publisher","DOI":"10.1002\/jps.23907"},{"key":"ref28\/cit28","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.5b00089"},{"key":"ref29\/cit29","doi-asserted-by":"publisher","DOI":"10.1021\/acs.langmuir.6b02267"},{"key":"ref30\/cit30","doi-asserted-by":"publisher","DOI":"10.1021\/acs.langmuir.7b03790"}],"container-title":["Molecular Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.0c00093","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T18:10:30Z","timestamp":1681755030000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/doi\/10.1021\/acs.molpharmaceut.0c00093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,22]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7,6]]}},"alternative-id":["10.1021\/acs.molpharmaceut.0c00093"],"URL":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.0c00093","relation":{},"ISSN":["1543-8384","1543-8392"],"issn-type":[{"value":"1543-8384","type":"print"},{"value":"1543-8392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,22]]}}}